OncoMed Pharmaceuticals, Inc.
) recently initiated a phase Ib/II study on its oncology
candidate, demcizumab. Demcizumab is being developed for the
treatment of patients suffering from ovarian cancer.
The phase Ib/II study will evaluate demcizumab in combination
with Taxol (paclitaxel) in patients suffering from
platinum-resistant ovarian cancer, fallopian tube cancer or
primary peritoneal cancer. OncoMed will proceed with the phase II
study on the candidate after a phase Ib safety study is
The phase II study will be evaluating progression-free survival
and response rate of the patients treated with the demcizumab and
Taxol combination. The study will also determine overall
survival, biomarker endpoints and safety of the candidate.
We note that OncoMed has conducted three more phase Ib studies on
demcizumab earlier in combination with chemotherapy regimens in
patients suffering from first-line pancreatic cancer, first- or
second-line colorectal cancer and first-line non-small cell lung
cancer. The phase Ib studies in patients suffering from
pancreatic cancer and non-small cell lung cancer are enrolling
We are encouraged by the company's progress with its oncology
candidate. Meanwhile, the oncology market looks extremely
competitive with the presence of big companies like
Moreover, most of the candidates at OncoMed are in early stages
of development. We expect investor focus to remain on the
company's pipeline going forward.
OncoMed currently carries a Zacks Rank #3 (Hold). Other stocks,
), are comparatively better positioned with a Zacks Rank #1
ACTELION LTD (ALIOF): Get Free Report
BAYER A G -ADR (BAYRY): Free Stock Analysis
ONCOMED PHARMA (OMED): Free Stock Analysis
ROCHE HLDG LTD (RHHBY): Get Free Report
To read this article on Zacks.com click here.